Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 359-361

  Perik, P J ^a   Rikhof, B ^a   de Jong, F A ^b   Verweij, J ^b   Gietema, J A ^a   van der Graaf, W T A ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiotoxicity; GIST; Imatinib mesylate; NT proBNP; Troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BLEOMYCIN; CAPECITABINE; CISPLATIN; ETOPOSIDE; IMATINIB; TROPONIN T;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CARCINOMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GERM CELL TUMOR; HEART FUNCTION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PIPERAZINES; PROBABILITY; PROSPECTIVE STUDIES; PYRIMIDINES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TROPONIN T;

EID: 38849140867     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm468     Document Type: Article

References (14)

1. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
2. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxity of the cancer therapeutic agent imatinib mesylate, Nat Med 2006; 12: 908-916.
3. Ataliah E, Kantarjian H, Cortes J. In reply to 'cardiotoxicity of the cancer therapeutic agent imatnib mesylate'. Nat Med 2007; 13: 14-16.
4. Rosti G, Martinelli G, Baccarani M. In reply to 'cardiatoyicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 15-16.
5. Verweij J, Casali PG, Kotasek D et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patents: analyis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43: 974-978.
6. Force T. In reply to 'cardictoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 15-16.
7. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dounction. J Am Coll Cardiol 2006; 47: 345-353.
8. Hunt SA, Abraham WT, Chin MH et al, ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: E154-e235.
9. Hess G, Runkel S, Zdunek D, Hitzler WE. N-terminal pro-brain natriuretic; peptide (NT-proBNP) in healthy blood donors and in patents from general practitioners with and without a diagnosis of cardiac disease. Clin Lab 2005; 51: 167-172.
10. Januzzi JL, van Kimmenade R, Lainchbury J et al, NT-proBNP testing for diagnosis and-short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 pallents: The International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330-337.
11. Kouloubinis A, Kaklamanis L, Ziras N et al. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patents treated with cardiotoxic chemotherapy. Int J Cardiol 2007; In press.
12. Park YH, Park HJ, Kim BS et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006; 243: 16-22.
13. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-222.
14. Kilickap S, Barista I, Akgul E et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798-804.